161.25 USD
-2.43 (-1.48%)
Taking everything into account, JAZZ scores 4 out of 10 in our fundamental rating. JAZZ was compared to 190 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. JAZZ scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
In the past year JAZZ had a positive cash flow from operations.
In multiple years JAZZ reported negative net income over the last 5 years.
In the past 5 years JAZZ always reported a positive cash flow from operatings.
1.2 Ratios
JAZZ's Return On Assets of -3.24% is fine compared to the rest of the industry. JAZZ outperforms 74.21% of its industry peers.
The Return On Equity of JAZZ (-9.31%) is better than 74.74% of its industry peers.
JAZZ has a Return On Invested Capital of 3.95%. This is amongst the best in the industry. JAZZ outperforms 82.11% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.84%.
The last Return On Invested Capital (3.95%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
JAZZ's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 10.92%, JAZZ belongs to the top of the industry, outperforming 83.16% of the companies in the same industry.
In the last couple of years the Operating Margin of JAZZ has declined.
The Gross Margin of JAZZ (88.49%) is better than 90.00% of its industry peers.
JAZZ's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
JAZZ has less shares outstanding than it did 1 year ago.
JAZZ has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, JAZZ has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.52, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.52, JAZZ perfoms like the industry average, outperforming 56.32% of the companies in the same industry.
The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.33, JAZZ belongs to the top of the industry, outperforming 83.68% of the companies in the same industry.
JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
JAZZ has a worse Debt to Equity ratio (1.09) than 74.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.52 |
ROIC/WACC0.54
WACC7.35%
2.3 Liquidity
A Current Ratio of 1.65 indicates that JAZZ should not have too much problems paying its short term obligations.
JAZZ has a worse Current ratio (1.65) than 68.95% of its industry peers.
A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.44, JAZZ is doing worse than 64.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for JAZZ have decreased strongly by -58.39% in the last year.
The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
The Revenue has been growing slightly by 4.14% in the past year.
The Revenue has been growing by 13.48% on average over the past years. This is quite good.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 7.67% on average per year.
The Revenue is expected to grow by 7.06% on average over the next years.
EPS Next Y-61.17%
EPS Next 2Y4.25%
EPS Next 3Y6.22%
EPS Next 5Y7.67%
Revenue Next Year4.61%
Revenue Next 2Y5.53%
Revenue Next 3Y6.22%
Revenue Next 5Y7.06%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.76, the valuation of JAZZ can be described as rather expensive.
Based on the Price/Earnings ratio, JAZZ is valued cheaper than 80.53% of the companies in the same industry.
JAZZ is valuated rather cheaply when we compare the Price/Earnings ratio to 27.25, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 7.00, the valuation of JAZZ can be described as very cheap.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaper than 92.63% of the companies in the same industry.
JAZZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.76 | ||
| Fwd PE | 7 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaper than 85.79% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaply inside the industry as 93.16% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.91 | ||
| EV/EBITDA | 11.01 |
4.3 Compensation for Growth
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.62
EPS Next 2Y4.25%
EPS Next 3Y6.22%
5. Dividend
5.1 Amount
JAZZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:JAZZ (1/13/2026, 9:47:01 AM)
161.25
-2.43 (-1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners104.02%
Inst Owner Change0.21%
Ins Owners2.48%
Ins Owner Change-0.78%
Market Cap9.80B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts85.22
Price Target217.63 (34.96%)
Short Float %8.56%
Short Ratio4.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)2.57%
PT rev (3m)14.13%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)11.36%
EPS NY rev (1m)-0.12%
EPS NY rev (3m)53.06%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-0.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.76 | ||
| Fwd PE | 7 | ||
| P/S | 2.36 | ||
| P/FCF | 7.91 | ||
| P/OCF | 7.04 | ||
| P/B | 2.48 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.01 |
EPS(TTM)8.16
EY5.06%
EPS(NY)23.03
Fwd EY14.28%
FCF(TTM)20.39
FCFY12.64%
OCF(TTM)22.9
OCFY14.2%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.62
Graham Number109.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROCE | 5% | ||
| ROIC | 3.95% | ||
| ROICexc | 5.1% | ||
| ROICexgc | 55.75% | ||
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% | ||
| FCFM | 29.8% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.8 | ||
| Cap/Depr | 22.29% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 122.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.52 |
F-Score5
WACC7.35%
ROIC/WACC0.54
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-61.17%
EPS Next 2Y4.25%
EPS Next 3Y6.22%
EPS Next 5Y7.67%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.61%
Revenue Next 2Y5.53%
Revenue Next 3Y6.22%
Revenue Next 5Y7.06%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-59.85%
EBIT Next 3Y5.83%
EBIT Next 5Y7.65%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
Can you provide the financial health for JAZZ stock?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -61.17% in the next year.